Selincro

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

nalmefene

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Unruhe, Unwohlsein und Zittern bei Opioid-Entzugssyndrom
Die 51-jährige Patientin nahm erstmalig Nalmefen (Selincro®) vor Besuch eines Festes ein. Eine Viertelstunde nach der Einnahme… (More)
Is this relevant?
2018
2018
Selincro (Nalméfène) et réduction des risques en alcoologie : réduire la consommation d'alcool des patients alcoolodépendants
 
Is this relevant?
2016
2016
Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood.
BACKGROUND AND PURPOSE The opioid antagonist nalmefene (selincro®) was approved for alcohol-related disorders by the European… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
STREAM: Elucidating How Alcohol Use Disorders are Managed in UK General Practice Today.
AIMS To characterize a contemporaneous cohort of UK general practice patients with alcohol use disorder and describe their… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2015
2015
Severe opioid withdrawal syndrome after a single dose of nalmefene
Case 1 A 43-year-old man was brought by ambulance to the emergency department (ED) with severe agitation and clinical signs of… (More)
Is this relevant?
Review
2015
Review
2015
Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
As part of its single technology appraisal process, the National Institute for Health and Care Excellence (NICE) invited the… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
2015
2015
[Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions].
Nalmefene (Selincro®) is a selective opioid receptor antagonist, licensed in April 2014 in Switzerland for the reduction of… (More)
Is this relevant?
Review
2014
Review
2014
[Nalmefene (Selincro) orally].
  • Journal de pharmacie de Belgique
  • 2014
 
Is this relevant?
2014
2014
â–¼Nalmefene for alcohol dependence.
  • Drug and therapeutics bulletin
  • 2014
The burden of morbidity and mortality resulting from alcohol dependence is high. World Health Organization (WHO) figures suggest… (More)
Is this relevant?
Review
2013
Review
2013
Nalmefene: a review of its use in the treatment of alcohol dependence.
The opioid system modulator nalmefene (Selincro®) is approved in the EU for as-needed use to reduce alcohol consumption in… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?